Skip to main content
Top
Published in: Esophagus 2/2014

01-04-2014 | Case Report

Inflammatory myofibroblastic tumor in the esophagus after treatment for superficial esophageal cancer

Authors: Takeo Bamba, Satoru Nakagawa, Hiroshi Yabusaki, Masaki Aizawa, Atsushi Matsuki, Takashi Kawasaki, Keiichi Homma, Atsushi Nashimoto

Published in: Esophagus | Issue 2/2014

Login to get access

Abstract

A 76-year-old man was referred to our hospital for treatment of a submucosal tumor in the esophagus. The patient had a history of superficial esophageal cancer treated by endoscopic resection and radiation. Positron emission tomography showed intense localized uptake of fluorodeoxyglucose on the esophageal mass. Transthoracic esophagectomy and reconstruction with a gastric tube were performed. Histopathological examination revealed that the tumor consisted of a proliferation of atypical spindle cells with infiltration of many inflammatory cells. The spindle cells were positive for vimentin, alpha smooth muscle actin, and anaplastic lymphoma kinase immunostaining. The Ki-67 labeling index was 10–20 %. The tumor was finally diagnosed as inflammatory myofibroblastic tumor. Late phase inflammation caused by radiation potentially had an effect on the occurrence of the tumor in this case. For tumors of the irradiated esophagus, especially, careful pretreatment examination and treatment strategies with consideration of the radiation damage are important to obtaining a favorable outcome.
Literature
1.
go back to reference Coffin CM, Hornick JL, Fletcher CD. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol. 2007;31:509–20.PubMedCrossRef Coffin CM, Hornick JL, Fletcher CD. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol. 2007;31:509–20.PubMedCrossRef
2.
go back to reference Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours: where are we now? J Clin Pathol. 2008;61:428–37.PubMedCrossRef Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours: where are we now? J Clin Pathol. 2008;61:428–37.PubMedCrossRef
3.
go back to reference Coffin CM, Watterson J, Priest JR, Dehner LP. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol. 1995;19:859–72.PubMedCrossRef Coffin CM, Watterson J, Priest JR, Dehner LP. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol. 1995;19:859–72.PubMedCrossRef
4.
go back to reference Cook JR, Dehner LP, Collins MH, Ma Z, Morris SW, Coffin CM, et al. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol. 2001;25:1364–71.PubMedCrossRef Cook JR, Dehner LP, Collins MH, Ma Z, Morris SW, Coffin CM, et al. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol. 2001;25:1364–71.PubMedCrossRef
5.
go back to reference Kurihara K, Mizuseki K, Ichikawa M, Okada K, Miyata Y. Esophageal inflammatory pseudotumor mimicking malignancy. Intern Med. 2001;40:18–22.PubMedCrossRef Kurihara K, Mizuseki K, Ichikawa M, Okada K, Miyata Y. Esophageal inflammatory pseudotumor mimicking malignancy. Intern Med. 2001;40:18–22.PubMedCrossRef
6.
go back to reference Meissner K. Late radiogenic small bowel damage: guidelines for the general surgeon. Dig Surg. 1999;16:169–74.PubMedCrossRef Meissner K. Late radiogenic small bowel damage: guidelines for the general surgeon. Dig Surg. 1999;16:169–74.PubMedCrossRef
7.
go back to reference Jindal T, Kumar A, Dutta R, Kumar R. Combination of (18)-FDG and (68)Ga-DOTATOC PET-CT to differentiate endobronchial carcinoids and inflammatory myofibroblastic tumors. J Postgrad Med. 2009;55:272–4.PubMedCrossRef Jindal T, Kumar A, Dutta R, Kumar R. Combination of (18)-FDG and (68)Ga-DOTATOC PET-CT to differentiate endobronchial carcinoids and inflammatory myofibroblastic tumors. J Postgrad Med. 2009;55:272–4.PubMedCrossRef
8.
go back to reference Babar-Craig H, Gill H, Almeyda R, Wong WL, Farrell R. Inflammatory pseudotumour of the neck with multifocal sites on positron emission tomography scan imaging. J Laryngol Otol. 2005;119:219–21.PubMed Babar-Craig H, Gill H, Almeyda R, Wong WL, Farrell R. Inflammatory pseudotumour of the neck with multifocal sites on positron emission tomography scan imaging. J Laryngol Otol. 2005;119:219–21.PubMed
9.
go back to reference Wolf BC, Khettry U, Leonardi HK, Neptune WB, Bhattacharyya AK, Legg MA. Benign lesions mimicking malignant tumors of the esophagus. Hum Pathol. 1988;19:148–54.PubMedCrossRef Wolf BC, Khettry U, Leonardi HK, Neptune WB, Bhattacharyya AK, Legg MA. Benign lesions mimicking malignant tumors of the esophagus. Hum Pathol. 1988;19:148–54.PubMedCrossRef
10.
go back to reference Li J, Liu F, Wang Z, Liu Q, Wang Y, Zhou Q, et al. Inflammatory pseudotumor of the esophagus—GI image. J Gastrointest Surg. 2010;14:195–8.PubMedCrossRef Li J, Liu F, Wang Z, Liu Q, Wang Y, Zhou Q, et al. Inflammatory pseudotumor of the esophagus—GI image. J Gastrointest Surg. 2010;14:195–8.PubMedCrossRef
11.
go back to reference Miyata H, Yamasaki M, Takiguchi S, Nakajima K, Fujiwara Y, Nishida T, et al. Salvage esophagectomy after definitive chemoradiotherapy for thoracic esophageal cancer. J Surg Oncol. 2009;100:442–6.PubMedCrossRef Miyata H, Yamasaki M, Takiguchi S, Nakajima K, Fujiwara Y, Nishida T, et al. Salvage esophagectomy after definitive chemoradiotherapy for thoracic esophageal cancer. J Surg Oncol. 2009;100:442–6.PubMedCrossRef
12.
go back to reference Privette A, Fisk P, Leavitt B, Cooper K, McCahill L. Inflammatory myofibroblastic tumor presenting with esophageal obstruction and an inflammatory syndrome. Ann Thorac Surg. 2008;86:1364–7.PubMedCrossRef Privette A, Fisk P, Leavitt B, Cooper K, McCahill L. Inflammatory myofibroblastic tumor presenting with esophageal obstruction and an inflammatory syndrome. Ann Thorac Surg. 2008;86:1364–7.PubMedCrossRef
13.
go back to reference Stelow EB, Shami VM, Moskaluk CA, Burns KG, Legallo RD, Jones DR. Esophageal inflammatory myofibroblastic tumor sampled by EUS-FNA. Gastrointest Endosc. 2010;72:209–10.PubMedCrossRef Stelow EB, Shami VM, Moskaluk CA, Burns KG, Legallo RD, Jones DR. Esophageal inflammatory myofibroblastic tumor sampled by EUS-FNA. Gastrointest Endosc. 2010;72:209–10.PubMedCrossRef
14.
go back to reference Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E, Griffin CA. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol. 2001;14:569–76.PubMedCrossRef Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E, Griffin CA. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol. 2001;14:569–76.PubMedCrossRef
Metadata
Title
Inflammatory myofibroblastic tumor in the esophagus after treatment for superficial esophageal cancer
Authors
Takeo Bamba
Satoru Nakagawa
Hiroshi Yabusaki
Masaki Aizawa
Atsushi Matsuki
Takashi Kawasaki
Keiichi Homma
Atsushi Nashimoto
Publication date
01-04-2014
Publisher
Springer Japan
Published in
Esophagus / Issue 2/2014
Print ISSN: 1612-9059
Electronic ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-013-0399-z

Other articles of this Issue 2/2014

Esophagus 2/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine